-
Constructing Experimental Designs for Discrete-Choice Experiments
-
Prospective Observational Studies to Assess Comparative Effectiveness
-
Modeling Good Research Practices - Overview: Report 1
-
Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research
-
Conceptualizing a Model: Report 2
-
State-Transition Modeling: Report 3
-
Modeling Using Discrete Event Simulation: Report 4
-
Dynamic Transmission Modeling: Report 5
-
Model Parameter Estimation and Uncertainty Analysis: Report 6
-
Model Transparency and Validation: Report 7
-
Content Validity - Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation Part 1
-
Content Validity – Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation Part 2
-
Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making Report 1
-
Conducting Indirect Treatment Comparison and Network Meta-Analysis Studies Report 2
-
Conjoint Analysis Applications in Health - A Checklist
-
Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy - Report of ISPOR Risk–Benefit Management Working Group
-
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations - ISPOR drug cost task force report - Part I
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective - ISPOR drug cost task force report - Part II
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective - ISPOR drug cost task force report - Part III
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and US Government Payers Perspectives ISPOR drug cost task force report - Part IV
Questions?
For any questions about this report please contact us.